Fractyl Health (GUTS) Q1 2026 earnings summary

Executive summary

• Achieved net income of $9.2 million for Q1 2026, a turnaround from a net loss of $23.7 million in Q1 2025, driven by a $30.1 million non-cash gain from warrant liabilities.

• Advanced clinical programs: Revita completed pivotal cohort randomization and showed durable weight maintenance post-GLP-1 therapy; Rejuva received CTA authorization in the Netherlands and is advancing to first-in-human dosing in H2 2026.

• Cash and cash equivalents totaled $63.2 million as of March 31, 2026, expected to fund operations into early 2027, though substantial doubt exists about the ability to continue as a going concern beyond that period.

• Revita positioned as a durable solution for post-GLP-1 weight regain, with strong clinical validation and growing physician enthusiasm.

• Key clinical milestones for Revita and Rejuva achieved, with regulatory progress in the EU and Australia.

Financial highlights

• Q1 2026 net income was $9.2 million, compared to a net loss of $23.7 million in Q1 2025, driven by a $30.1 million non-cash change in warrant liabilities.

• Adjusted EBITDA was negative $18.0 million, improving from negative $23.1 million in Q1 2025.

• Research and development expenses decreased to $15.6 million from $19.4 million year-over-year; SG&A stable at $5.2 million.

• Total operating expenses decreased 15.9% year-over-year to $20.8 million, mainly due to lower R&D spending.

• Cash and cash equivalents stood at $63.2 million as of March 31, 2026.

Outlook and guidance

• Cash runway extends into early 2027, covering anticipated pivotal data readout and potential De Novo submission.

• No plans to raise capital before pivotal data; ATM facility remains closed.

• Top-line six-month pivotal data for Revita expected in early Q4 2026; De Novo marketing application submission planned for late Q4 2026.

• First-in-human dosing and preliminary data for RJVA-001 anticipated in H2 2026.

• Management expects existing cash to fund operations through multiple key clinical and regulatory milestones in 2026, but not for at least twelve months from the report issuance date.